• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Americans' Uncertainty Over Drugs


At least a third of Americans believe that the FDA only approves drugs that are extremely effective and have no serious side effects.

A study revealed that Americans may not be aware of uncertainties about drug benefits and harms, according to a report in the Archives of Internal Medicine. Also, many adults believe that the Food and Drug Administration only approves drugs that are very effective or without serious side effects.

The article points out that uncertainties about drugs are greatest in the first years after they are approved, during which time the drugs are on the market. The authors used Zetia and Vytorin, two cholesterol-lowering drugs, as an example. Both drugs were found to have no clinical benefit, but not before sales exceeded $1 billion.

The study revealed that a quarter of participants believed the FDA wouldn’t approve a drug if it had serious side effects and a third believed the agency would only approve “extremely effective” drugs.

Participants were given some hypothetical drugs to choose and split into three groups, each given different information. For the most part, participants chose the drug for which there was less uncertainty.

Overall, the authors recommended that the FDA communicates what it does and doesn’t know about the efficacy of drugs, even if it’s just a brief explanation in a TV advertisement.

“There are important gaps in what people know about prescription drugs — gaps that undoubtedly contribute to the rapid uptake of drugs despite uncertainty about benefit and harm,” the authors wrote.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice